Climb Bio, Inc. (CLYM)
D
Pipeline Grade
Financial Position (from SEC Filings)
$8.4M
Cash & Equivalents
$14.4M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$802M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-04-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07043946 | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | PHASE2 | Recruiting | 24 |
| NCT07096843 | A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | PHASE2 | Recruiting | 45 |
| NCT07248865 | A Phase 1 Study of CLYM116 in Normal Healthy Volunteers | PHASE1 | Recruiting | 48 |
| NCT07011043 | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | PHASE1 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.